Some Recent Publications

Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease.Lin TT, Norris K, Heppel NH, Pratt G, Allan JM, Allsup DJ, Bailey J, Cawkwell L, Hills R, Grimstead JW, Jones RE, Britt-Compton B, Fegan C, Baird DM, Pepper C. Br J Haematol. 2014 Jul 3. doi: 10.1111/bjh.13023. [Epub ahead of print]

Proteomics Based Strategies to Identify Proteins Relevant to Chronic Lymphocytic Leukaemia. Alsagaby SA, Khanna S, Hart KW, Pratt G, Fegan C, Pepper C, Brewis IA, Brennan P. J Proteome Res. 2014 Jul 1. [Epub ahead of print].

Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukaemia. Walsby E, Buggins A, Devereux S, Jones C, Pratt G, Brennan P, Fegan C, Pepper C. Blood. 2014 Jun 5;123(23):3607-17. doi: 10.1182/blood-2013-12-544569. Epub 2014 Mar 17.

CD49d Is the Strongest Flow Cytometry-Based Predictor of Overall Survival in Chronic Lymphocytic Leukemia. Bulian P, Shanafelt TD, Fegan C, Zucchetto A, Cro L, Nückel H, Baldini L, Kurtova AV, Ferrajoli A, Burger JA, Gaidano G, Del Poeta G, Pepper C, Rossi D, Gattei V. J Clin Oncol. 2014 Feb 10. [Epub ahead of print]

A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. Speedy HE, Di Bernardo MC, Sava GP, Dyer MJ, Holroyd A, Wang Y, Sunter NJ, Mansouri L, Juliusson G, Smedby KE, Roos G, Jayne S, Majid A, Dearden C, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Rosenquist R, Catovsky D, Allan JM, Houlston RS. Nat Genet. 2014 Jan;46(1):56-60. doi: 10.1038/ng.2843. Epub 2013 Dec 1.

Blinatumomab induces autologous T cell killing of chronic lymphocytic leukemia cells. Wong R, Pepper C, Brennan P, Nagorsen D, Man S, Fegan C. Haematologica. 2013 Jun 28. [Epub ahead of print] PMID:23812940

The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells. Walsby EJ, Lazenby M, Pepper CJ, Knapper S, Burnett AK. Br J Haematol. 2013 Apr;161(1):57-67. doi: 10.1111/bjh.12215. Epub 2013 Jan 29. PMID:23356405

Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells. Hamilton E, Pearce L, Morgan L, Robinson S, Ware V, Brennan P, Thomas NS, Yallop D, Devereux S, Fegan C, Buggins AG, Pepper C. Br J Haematol. 2012 Sep;158(5):589-99. doi: 10.1111/j.1365-2141.2012.09191.x. Epub 2012 Jun 19.PMID: 22712573

The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. Walsby E, Pearce L, Burnett AK, Fegan C, Pepper C. Oncotarget. 2012 May;3(5):525-34. PMID: 22619113

Telomere dysfunction and its role in haematological cancer. Jones CH, Pepper C, Baird DM. Br J Haematol. 2012 Mar;156(5):573-87. doi: 10.1111/j.1365-2141.2011.09022.x. Epub 2012 Jan 11. Review. PMID: 22233151

Expansion of a CD8+PD-1+ replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Nunes CT, Wong R, Mason M, Fegan C, Man S, Pepper C. Clin Cancer Res. 2011 Dec 21. [Epub ahead of print] PMID: 22190592

Defining the prognosis of early stage chronic lymphocytic leukaemia patients. Pepper C, Majid A, Lin TT, Hewamana S, Pratt G, Walewska R, Gesk S, Siebert R, Wagner S, Kennedy B, Miall F, Davis ZA, Tracy I, Gardiner AC, Brennan P, Hills RK, Dyer MJ, Oscier D, Fegan C. Br J Haematol. 2011 Dec 15. doi: 10.1111/j.1365-2141.2011.08974.x. [Epub ahead of print] PMID:22171799

Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage. Britt-Compton B, Lin TT, Ahmed G, Weston V, Jones RE, Fegan C, Oscier DG, Stankovic T, Pepper C, Baird DM. Leukemia. 2011 Oct 11. doi: 10.1038/leu.2011.281. [Epub ahead of print] PMID:21986843

Co-operative Membrane Disruption Between Cell-penetrating Peptide and Cargo: Implications for the Therapeutic Use of the Bcl-2 Converter Peptide D-NuBCP-9-r8. Watkins CL, Sayers EJ, Allender C, Barrow D, Fegan C, Brennan P, Jones AT. Mol Ther. 2011 Sep 20. doi: 10.1038/mt.2011.175. [Epub ahead of print] PMID:21934653

A novel tumor antigen derived from enhanced degradation of bax protein in human cancers. Nunes CT, Miners KL, Dolton G, Pepper C, Fegan C, Mason MD, Man S. Cancer Res. 2011 Aug 15;71(16):5435-44. Epub 2011 Jun 22. PMID: 21697278

Two novel aspirin analogues show selective cytotoxicity in primary chronic lymphocytic leukaemia cells that is associated with dual inhibition of Rel A and COX-2. Pepper C, Mahdi JG, Buggins AG, Hewamana S, Walsby E, Mahdi E, Al-Haza’a A, Mahdi AJ, Lin TT, Pearce L, Morgan L, Bowen ID, Brennan P, Fegan C. Cell Prolif. 2011 Aug;44(4):380-90. doi: 10.1111/j.1365-2184.2011.00760.x. Epub 2011 Jun 6. PMID:21645153

CLL: a supplementary question? Pepper C, Fegan C. Blood. 2011 Feb 3;117(5):1439-40. PMID: 21292782

Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. Lin TT, Letsolo BT, Jones RE, Rowson J, Pratt G, Hewamana S, Fegan C, Pepper C, Baird DM. Blood. 2010 Sep 16;116(11):1899-907. Epub 2010 Jun 10. PMID: 20538793

The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib. Walsby EJ, Pratt G, Hewamana S, Crooks PA, Burnett AK, Fegan C, Pepper C. Mol Cancer Ther. 2010 Jun;9(6):1574-82. Epub 2010 Jun 1. PMID: 20515939

Genetic modification of primary chronic lymphocytic leukemia cells with a lentivirus expressing CD38. Pearce L, Morgan L, Lin TT, Hewamana S, Matthews RJ, Deaglio S, Rowntree C, Fegan C, Pepper C, Brennan P. Haematologica. 2010 Mar;95(3):514-7. PMID: 20207849

NF-kappaB as a prognostic marker and therapeutic target in chronic lymphocytic leukemia. Pepper C, Hewamana S, Brennan P, Fegan C. Future Oncol. 2009 Sep;5(7):1027-37. Review. PMID: 19792971

Cellular uptake, distribution and cytotoxicity of the hydrophobic cell penetrating peptide sequence PFVYLI linked to the proapoptotic domain peptide PAD. Watkins CL, Brennan P, Fegan C, Takayama K, Nakase I, Futaki S, Jones AT. J Control Release. 2009 Dec 16;140(3):237-44. Epub 2009 May 4. PMID: 19409429

Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. Hewamana S, Lin TT, Rowntree C, Karunanithi K, Pratt G, Hills R, Fegan C, Brennan P, Pepper C. J Clin Oncol. 2009 Feb 10;27(5):763-9. Epub 2009 Jan 5. PMID: 19124804

The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Hewamana S, Lin TT, Jenkins C, Burnett AK, Jordan CT, Fegan C, Brennan P, Rowntree C, Pepper C. Clin Cancer Res. 2008 Dec 15;14(24):8102-11. PMID:19088025

Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Pepper C, Lin TT, Pratt G, Hewamana S, Brennan P, Hiller L, Hills R, Ward R, Starczynski J, Austen B, Hooper L, Stankovic T, Fegan C. Blood. 2008 Nov 1;112(9):3807-17. Epub 2008 Jul 3. PMID: 18599795

Highly purified CD38 sub-populations show no evidence of preferential clonal evolution despite having increased proliferative activity when compared with CD38 sub-populations derived from the same chronic lymphocytic leukaemia patient. Lin TT, Hewamana S, Ward R, Taylor H, Payne T, Pratt G, Baird D, Fegan C, Pepper C. Br J Haematol. 2008 Aug;142(4):595-605. Epub 2008 May 22. PMID: 18503580

The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML, Jordan CT, Neelakantan S, Crooks PA, Burnett AK, Pratt G, Fegan C, Rowntree C, Brennan P, Pepper C. Blood. 2008 May 1;111(9):4681-9. Epub 2008 Jan 28. PMID: 18227347

Comments

No comments.

Leave a Reply

Your email address will not be published. Required fields are marked *